Abstract
INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide and has a dismal 5-year survival rate of 15% [1] . In pathological Stage III (N2) non-small-cell lung cancer (NSCLC), considerable advancement is found in the surgical field, making it debatable whether surgical resection for this stage is indicated. Even with aggressive multimodality treatment including curative surgery, the long-term outcomes are poor, with a 5-year overall survival rate of <35% [2] . Postoperative recurrence is the most common cause of death and is the main obstacle for long-term survival in lung cancer patients; however, recently developed treatment modalities, including new chemotherapeutic agents such as epidermal growth factor receptor tyrosine kinase inhibitors, are effective at reducing postoperative recurrence. Therefore, some patients with Stage III (N2) NSCLC who received aggressive multimodality treatment of recurrence showed longterm post-recurrence survival (PRS). Many studies have been performed to identify prognostic factors for PRS in patients with early-stage lung cancer. Hung et al. [3] showed that treatment for initial recurrence was a prognostic predictor of PRS in patients with resected Stage I NSCLC with local recurrence. In our previous study, we demonstrated that a good response to the initial treatment of recurrence and a longer recurrence-free interval (RFI) were significant predictors of better PRS in patients with completely resected Stage I NSCLC [4] . Unlike Stage I NSCLC, patients with Stage III (N2) NSCLC generally undergo chemotherapy or chemoradiotherapy after curative resection, and it is therefore challenging to select the appropriate treatment modality and chemotherapeutic agents to treat recurrent cancer. Therefore, the number of patients who receive aggressive multimodality treatment of recurrence is relatively small. For this reason, identifying prognostic factors for PRS might provide evidence regarding the efficacy of aggressive treatments, thereby facilitating the development of guidelines for the selection of treatment modalities for Stage III (N2) NSCLC.
This study was conducted to evaluate the prognostic factors for PRS, with a focus on patients who underwent curative resection for Stage IIIA (N2) NSCLC.
MATERIALS AND METHODS
This study retrospectively reviewed the records of 245 patients who underwent surgery for pathological Stage III (N2) NSCLC at the Seoul National University Bundang Hospital between June 2003 and December 2014. Patients who had metachronous or synchronous multiple primary lung cancer, pathological Stage IV cancer or who underwent incomplete resection were excluded. The preoperative staging workup was as follows. Positron emission tomography/computed tomography (PET/CT) has been available since 2004 and was conducted in 218 (89%) of the 245 patients. Since 2013, endobronchial ultrasound fine-needle aspiration has been performed when enlarged mediastinal lymph nodes (MLNs) are observed on chest CT or hypermetabolism is seen on PET/CT. Neoadjuvant chemotherapy or chemoradiotherapy was usually performed when metastasis to the MLNs was pathologically confirmed. However, if node metastasis was in a single station and not bulky, surgical resection was performed without neoadjuvant therapy according to the surgeon's preference. Complete resection of lung cancer and dissection of the MLNs were routinely performed by video-assisted thoracic surgery or open thoracotomy. The disease stage was determined based on the 7th edition of the tumour-node-metastasis (TNM) classification.
The methods of follow-up and diagnosis of recurrence used in this study were previously described [4] . Patients were followed up every 3 months for the first 2 years and then every 6 months for an additional 3 years. Data analysed in this study included patient history, physical examination findings, chest radiography and tumour markers. A contrast-enhanced chest CT scan was taken every 3 months for the first 2 years and then every 6 months thereafter. If recurrence was suspected either based on newly presenting symptoms or scheduled tests, PET/CT was performed. The final diagnosis of recurrence was confirmed by the histopathological examination of the samples obtained from surgery or biopsy. If it was impossible to diagnose recurrence histopathologically, a recurrent malignancy was no longer suspected if a clinical and radiological follow-up period of at least 6 months went by with no evidence of active malignancy. During the follow up, if a new part-solid tumour developed, which was not adjacent to the previously resected mass, this newly formed partsolid tumour was considered as metachronous double primary cancer and as not recurrence. Enrolled patients were followed up until 31 December 2016. Follow-up duration was calculated between the date of operation and the date of death in deceased patients or 31 December 2016 in living patients.
The clinicopathological variables before recurrence were collected, and the following post-recurrence data were evaluated: symptoms of recurrence, the recurrence pattern (loco-regional, distant or both), the treatment modality (surgery, chemotherapy, chemoradiotherapy, radiotherapy or supportive care), the use of targeted agents and the RFI between the date of surgery and the date when recurrence was initially identified. The recurrence pattern was classified by the first site of recurrence. Loco-regional recurrence (LRR) was defined as recurrence in the ipsilateral hemithorax, including the resection margin, ipsilateral lung and pleura or the MLNs, and distant metastasis (DM) was defined as recurrence in the contralateral hemithorax or extrathoracic organs. The primary end point in this study was survival after diagnosis of recurrent cancer. PRS was defined as the time in months from the date of recurrent cancer diagnosis to death from any cause or the last date the patient was known to be alive. Patients known to be alive at the last contact were censored. A Cox proportional hazards model was used for univariable analysis and multivariable analysis. A forward stepwise selection procedure was implemented, with a P-value threshold of 0.05 for inclusion in the multivariable analysis. Statistical significance was accepted when the P-value was <0.05. All data were analysed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS

Patient characteristics
In total, 245 patients underwent surgery for pathological Stage III (N2) NSCLC, 167 (67%) patients were men and the mean age was 62.0 years. Neoadjuvant therapy was performed in 54 patients. Of the 245 patients who received treatment during the study period and were reviewed, 124 (51%) patients who experienced recurrence were enrolled in this study. Eighty-one (65%) of these patients were men, and their mean age was 62.6 years (range 34-84 years). Seventy-one (57%) patients were ever-smokers. Twenty-seven (22%) patients received neoadjuvant therapy. The extent of resection was lobectomy in 98 (79%) patients, bilobectomy in 14 (11%) patients and pneumonectomy in 12 (10%) patients. Pathological stage T1/2 disease was found in 93 (75%) patients, and stage T3/4 cancer was found in 31 (25%) patients. The median number of dissected lymph nodes (LNs) and positive LNs was 24 (range 16-51) and 4 (range 1-46), respectively. Metastasis to both N1 and N2 stations was found in 95 (77%) patients, and skip N2 metastasis was found in 29 (23%) patients. Seventy-seven (62%) patients had a single-station N2 metastasis, and 47 (38%) patients had N2 metastasis in 2 or more stations. The pathological examination of the resected specimens confirmed adenocarcinoma in 85 (69%) patients, squamous cell carcinoma in 23 (19%) patients and another type of cancer in 16 (12%) patients. After the operation, 218 (89%) patients underwent adjuvant chemotherapy or chemoradiotherapy.
In comparison with the 121 patients who did not experience recurrence, lymphatic invasion, a large tumour size, higher T stage, metastasis to both N1 and N2 stations, a large number of positive LNs and multistation N2 were found to be independent poor prognostic factors for recurrence-free survival in the multivariable analysis (Table 1) . There was no difference in RFS between patients with neoadjuvant therapy and those without. The 5-year recurrence-free survival rate was 41% (Fig. 1 ).
Characteristics of recurrence
For the 124 patients who experienced recurrence, the median follow-up duration was 39.8 months (range 6.1-139.1 months). Only 21 (17%) patients reported symptoms of recurrence, while recurrence was detected in the remaining 103 asymptomatic patients (83%) as follows: in 80 (78%) patients via routine chest CT, in 20 (19%) patients via PET/CT and in 3 (3%) patients via abnormal tumour markers. The mean RFI was 14.0 months (range 2-56 months), and 72 (58%) patients had an RFI of 12 months or less (short-RFI), while 52 (42%) patients had an RFI of longer than 12 months (long-RFI). A short-RFI was associated with neoadjuvant treatment and a high number of positive LNs, whereas a large tumour, lymphatic invasion, higher T stage, metastasis to both N1 and N2 stations and multistation N2, which were identified as prognostic factors for RFS, were not associated with a short-RFI. The mean RFI was significantly longer in asymptomatic patients (14.4 months) than in symptomatic patients (12.7 months) (P = 0.039). The recurrence patterns were as follows. LRR occurred in 38 (31%) patients, of whom 28 experienced ipsilateral MLN metastasis and 10 experienced LRR without ipsilateral MLN metastasis. Among the 28 patients with ipsilateral MLN metastasis, 17 had only MLN metastasis, and 11 patients had recurrence in the ipsilateral lung or stump site along with MLN metastasis. In the 10 patients without ipsilateral MLN metastasis, the most common site of recurrence was the ipsilateral lung, followed by recurrence at the stump site and pleura.
DM was confirmed in 33 (27%) patients; single metastasis occurred in 25 patients, while multiple metastases occurred in 8 patients. For single-organ metastasis, the most common site of metastasis was bone (n = 9), followed by the brain (n = 8), the contralateral lung (n = 4), the liver (n = 3) and other sites (n = 1, abdominal LN). The sites of multiple-organ metastases included the contralateral lung, liver, bone, adrenal gland and kidney. Both LRR and DM were confirmed simultaneously in 53 patients by chest CT or integrated PET/CT. Of these patients, 31 patients had both LRR and distant-organ metastasis, and 22 patients had LRR and bilateral lung metastasis ( Table 2) .
Treatment of recurrence
Except for 6 patients who only received supportive care, all patients received adequate treatment, as determined by multidisciplinary consultations. Of these 118 patients, 66 (53%) received only chemotherapy, including 8 who received targeted therapy, 18 (15%) who received concurrent or sequential chemoradiotherapy, 17 (14%) who received only radiotherapy and 17 (14%) who underwent surgery combined with chemotherapy or radiotherapy. Of the 17 patients who were treated with surgery, 5 had single distant-organ metastasis and 5 had both ipsilateral and DM ( Table 2 ). The most common surgical procedure was pulmonary resection followed by metastasectomy of the DM. When LRR was confined to the ipsilateral MLNs, concurrent or sequential chemoradiotherapy was the preferred treatment option.
Post-recurrence survival in patients who experienced recurrence
The median duration of PRS was 30.5 months (range 1-109 months), and 88 (71%) patients died during the follow-up period. The 1-, 3-and 5-year PRS rates were 91%, 55% and 36%, respectively, and 16 (13%) patients survived beyond 5 years after recurrence (Fig. 2) . After the treatment of recurrence, 50 (40%) patients did not experience further recurrence, but these patients did not show a significant difference in PRS compared with patients who did experience further recurrence. In terms of recurrence patterns, the 1-and 3-year PRS rates in those with LRR were 76% and 48%, respectively, and the corresponding rates were 52% and 32%, respectively, in those with DM. A statistically significant difference was found in the PRS rates between the patients who experienced LRR and those who experienced DM (P = 0.001). Moreover, the 1-and 3-year PRS rates in those with both LRR and DM were 83% and 47%, respectively, which were significantly different from the corresponding rates in those with DM only (P = 0.017) but were not significantly different from the rates in those who experienced LRR only. Univariable analysis identified symptoms of recurrence, treatment of recurrence, recurrence patterns and the RFI as prognostic factors for PRS (Table 3) , while the administration of radiotherapy and a shorter RFI were independent negative prognostic factors for PRS in the multivariable analysis ( Table 4) . The 1-, 3-and 5-year PRS rates in patients with a short-RFI and in those with a long-RFI were 60%, 27% and 21% and 87%, 60% and 24%, respectively. The mean PRS rate of patients treated with radiotherapy was 19%, which was the lowest among the various treatment modalities. Compared with patients who underwent other treatment modalities, patients with radiotherapy were older (P = 0.040), had more recurrence other than LNs (P = 0.036) and more recurrent symptoms (P = 0.007).
DISCUSSION
Due to the heterogeneity of Stage III (N2) NSCLC, neoadjuvant chemotherapy with or without radiotherapy followed by surgery, Figure 2 : The Kaplan-Meier survival curve for post-recurrence survival in 124 patients who experienced recurrence after surgical resection for Stage III (N2) non-small-cell lung cancer. surgery with adjuvant chemoradiotherapy and concurrent chemoradiotherapy without surgery have been recommended on a caseby-case basis, and it is difficult to say which treatment is best. As a result, recurrence patterns are also very diverse, with variation according to the treatment setting, surgical extent, the use of chemotherapeutic agents in neoadjuvant or adjuvant settings and the extent of radiation therapy. Therefore, few reports have evaluated PRS in patients with Stage III (N2) NSCLC, although many studies have focused on Stage I cancer after surgical resection. Lou et al. [5] reported that marked differences were found in the postresection recurrence patterns between patients with early-stage NSCLC and those with locally advanced NSCLC. The vast majority of cases of recurrence were distant metastases, especially to the brain in locally advanced disease, whereas only 25% of cases of recurrence involved loco-regional disease [5] . In this study, postoperative recurrence took place in 124 of the 245 (51%) patients who underwent curative resection with neoadjuvant or adjuvant therapy. Of the 124 patients who experienced recurrence, a shorter RFI, supportive care and the administration of radiotherapy were independent negative prognostic factors for PRS in the multivariable analysis. The RFI is a well-known prognostic factor in the setting of pulmonary metastasis from extrathoracic primary cancer, and some reports have evaluated the prognostic utility of RFI in primary lung cancer [6] [7] [8] . Two reasons have been proposed for early recurrence, which usually occurs within 3 months after complete resection. The first reason is that undetected cancer cells may be present. It has been suggested that occult micro-metastatic cancer cells, which are undetected by standard imaging methods, are often already present systemically at the time of surgery [9] . The second reason is related to the aggressiveness of the cancer itself. Even if no occult micro-metastatic cancer cells are already present, the handling of the tumour during surgery might sometimes lead to the dissemination of cancer cells. As the RFI is a direct reflection of tumour biology, tumours with a short RFI are very aggressive, and such tumours can grow despite chemotherapy or radiotherapy [10] . In this study, a short RFI was associated with neoadjuvant therapy and a large number of positive LNs. Patients who underwent neoadjuvant therapy usually showed a large tumour burden, such as multistation nodal metastasis, bulky metastatic nodes or single DM and were therefore more likely to have a short RFI. However, a comparison between the short RFI and the long RFI revealed no significant differences in the recurrence patterns or the number of metastatic organs.
It is well known that patients who undergo aggressive treatment for postoperative recurrence have better prognoses than those who receive supportive care. Shimada et al. [11] demonstrated that patients with Stage I NSCLC treated either surgically or nonsurgically had significantly better PRS than those who only received supportive care. The appropriate treatment of LRR included surgery for patients in an adequate general condition and radiotherapy in patients who were medically unsuitable for surgery. Therefore, in our study, patients who received radiotherapy for recurrence showed the lowest PRS among the various treatment modalities. Because patients with radiotherapy were older, had more recurrence other than LNs and recurrent symptoms compared with patients with other therapies, patients with radiotherapy might show a worse prognosis than those with other therapies. Surgery for postoperative LRR or single DM has been reported to be possible in up to 4% of patients [12] . In this study, surgical resection was performed in 17 (14%) patients, including 3 patients with LRR, 6 with DM and 8 with both, and pulmonary resection was most frequently performed, followed by the resection of DM. In particular, metastasis to only the ipsilateral MLNs was treated with concurrent chemoradiotherapy in patients with LRR.
However, in Stage III (N2) NSCLC, as recurrence is usually multiple, distant and complicated, systemic chemotherapy is the treatment of choice, and targeted therapy for the epidermal growth factor receptor mutation has been recently introduced. Third-generation agents with cisplatin have been administered as a standard treatment for patients with postoperative recurrence, and molecular targeting agents such as epidermal growth factor receptor tyrosine kinase inhibitors, inhibitors of the ALK fusion gene and immunotherapy have been indicated for recurrent NSCLC [13] [14] [15] [16] .
Among the 124 patients who experienced recurrence, 103 (over 80%) patients were asymptomatic. With the help of intensive postoperative surveillance and advancements in diagnostic methods, increases have occurred in the number of asymptomatic patients with recurrence, as well as in the early detection of recurrence, which is a noteworthy aspect of this study. The PRS was 19.1 months and 44.9 months in symptomatic and asymptomatic patients, respectively. Although the longer PRS of the asymptomatic patients might have been due to lead time bias, that factor does not entirely account for the discrepancy. The RFI of symptomatic patients was 12.7 months, which was shorter than that of the asymptomatic patients. Whether or not patients present with symptoms, early detection with the proper treatment has a positive influence on their survival because of more effective treatment with less of a tumour burden.
This study identified some factors that affected PRS. First, the recurrence pattern for the first recurrence was one such factor; the 3-year PRS rate of patients with DM was 32%, which was lower than the rates of 48% for patients with LRR only and 47% for patients with both LRR and DM. DM was statistically found to have the worst prognosis, but there was no significant difference between the LRR pattern and both LRR and DM. Similarly, Williams et al. [7] showed that non-lung recurrence, among various characteristics of recurrent cancer, had a negative effect on PRS. Sugimura et al. [8] reported 1-year PRS rates of 50% for patients with intrathoracic recurrence, 26% for those with extrathoracic recurrence and 28% for those with combined intrathoracic and extrathoracic recurrence. Patients with DM significantly had symptoms of recurrence and multiple LN metastasis compared with patients with LRR or both. However, there was no significant difference in neoadjuvant therapy, RFI, lymphovascular invasion and having radiotherapy (RT). Second, no difference in PRS was found between single-organ and multiple-organ metastasis in patients who had DM. Hung et al. [3] showed that PRS did not vary according to the type of recurrence and the number of recurrence sites, although their multivariable analysis showed that bone metastasis and liver metastasis were significantly associated with poorer PRS outcomes. Third, even though MLN dissection during surgery was performed, postoperative chemotherapy or radiotherapy was used in order to control MLN metastasis completely after the operation. Thus, metastasis to LNs other than the previous metastatic LNs might be associated with a poorer prognosis than the absence of LN metastasis, because this phenomenon also reflects the aggressiveness of the tumour. However, no difference in PRS was found between patients with MLN metastasis and those without LN metastasis. Fourth, no difference in PRS was found according to the number of stations of metastatic LNs, the number of metastatic LNs or the extent of metastatic LNs (N1 + N2 or skip N2). Although these are predictive factors for recurrence in Stage IIIA (N2) NSCLC, once recurrence develops, they are not prognostic factors for PRS. Finally, agents targeting the epidermal growth factor receptor mutation or the ALK fusion gene have shown favourable results for advanced or recurrent NSCLC [17] . However, the use of a targeted agent was not a significant prognostic factor in this study, even though patients who were treated with a targeted agent showed longer PRS. The reason for this finding may be the small number of patients who were treated with a targeted agent.
Limitations
This study has some limitations. First, as a retrospective singleinstitution study, patient selection bias and the use of multiple treatment protocols were inevitable. Second, this study had a relatively small number of patients. Propensity score matching could not be performed in order to reveal a causal relationship between radiotherapy and shorter PRS. Third, the recurrence patterns were determined by the first site of recurrence, although it was challenging to make this determination clearly.
CONCLUSION
In conclusion, the prognostic factors for recurrence-free survival were not associated with PRS, and a shorter RFI and radiotherapy for the treatment of recurrence were found to be negative prognostic factors for PRS. However, because we believe that poor prognosis was primarily due to having no option other than radiotherapy, further study is necessary to establish the causal relationship between radiotherapy and poor PRS.
